JP2009515953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515953A5 JP2009515953A5 JP2008541124A JP2008541124A JP2009515953A5 JP 2009515953 A5 JP2009515953 A5 JP 2009515953A5 JP 2008541124 A JP2008541124 A JP 2008541124A JP 2008541124 A JP2008541124 A JP 2008541124A JP 2009515953 A5 JP2009515953 A5 JP 2009515953A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- ketoglutarate
- pharmaceutically acceptable
- amino acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KPGXRSRHYNQIFN-UHFFFAOYSA-N α-Ketoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- 206010007709 Cartilage disease Diseases 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 229960002989 Glutamic Acid Drugs 0.000 claims 3
- 229960000310 ISOLEUCINE Drugs 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 229960003104 Ornithine Drugs 0.000 claims 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 229960002429 Proline Drugs 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- -1 alkaline earth metal salts Chemical class 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 201000008875 nutrition disease Diseases 0.000 claims 1
- 239000006069 physical mixture Substances 0.000 claims 1
- 150000003385 sodium Chemical group 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (12)
- 軟骨の障害の処置又は予防のための製剤調製物を製造するための、αケトグルタル酸又はαケトグルタル酸の薬学的に許容できる塩の使用。
- αケトグルタル酸又はαケトグルタル酸の薬学的に許容できる塩が、少なくとも１つのアミノ酸との薬学的に許容できる物理的混合物の形である、請求項１に記載の使用。
- アミノ酸が、グルタミン、グルタミン酸、アルギニン、オルニチン、ロイシン、イソロイシン、リジン、プロリン、及びこれらの組合せから選択される、請求項２に記載の使用。
- αケトグルタル酸の薬学的に許容できる塩が、アルカリ塩、若しくはアルカリ土類金属塩、又はそれらの組合せである、請求項１〜３のいずれか一項に記載の使用。
- αケトグルタル酸の薬学的に許容できる塩がαケトグルタル酸ナトリウムである、請求項１〜４のいずれか一項に記載の使用。
- 軟骨の障害の処置又は予防のための製剤調製物を製造するための、αケトグルタル酸と、アミノ酸、ジペプチド、又はトリペプチドとのアミドの使用。
- αケトグルタル酸とともにアミドを形成するアミノ酸が、グルタミン、グルタミン酸、アルギニン、オルニチン、リジン、プロリン、イソロイシン、及びロイシンから選択される、請求項６に記載の使用。
- αケトグルタル酸とともにアミドを形成するジペプチドが、グルタミンと、グルタミン酸、アルギニン、オルニチン、リジン、プロリン、イソロイシン、及びロイシンのうちの任意のものとのジペプチドである、請求項６に記載の使用。
- 前記軟骨の障害が体重減少及び／又は栄養障害；栄養不良；胃切除、部分的胃切除又は胃バンディングが関与する状態におけるものである、請求項１〜８のいずれか一項に記載の使用。
- 患者に投与する投与量が、前記物質１から１０００ｍｇ／ｋｇ体重／日の間隔である、請求項１〜９のいずれか一項に記載の使用。
- 患者に投与する投与量が、前記物質１０から４００ｍｇ／ｋｇ体重／日の間隔である、請求項１〜９のいずれか一項に記載の使用。
- 患者に投与する投与量が、前記物質の１０から１００ｍｇ／ｋｇ体重／日の間隔である、請求項１〜９のいずれか一項に記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59717205P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/050479 WO2007058612A1 (en) | 2005-11-15 | 2006-11-15 | Medicament for use in connection with cartilage impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515953A JP2009515953A (ja) | 2009-04-16 |
| JP2009515953A5 true JP2009515953A5 (ja) | 2010-07-08 |
Family
ID=38048916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541124A Pending JP2009515953A (ja) | 2005-11-15 | 2006-11-15 | 軟骨障害に関連した使用のための薬物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090312427A1 (ja) |
| EP (1) | EP1951218A4 (ja) |
| JP (1) | JP2009515953A (ja) |
| KR (1) | KR20080074182A (ja) |
| CN (2) | CN101843609A (ja) |
| AU (1) | AU2006316059A1 (ja) |
| BR (1) | BRPI0618599A2 (ja) |
| CA (1) | CA2629683A1 (ja) |
| HK (1) | HK1126128A1 (ja) |
| RU (1) | RU2454999C2 (ja) |
| WO (1) | WO2007058612A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618599A2 (pt) * | 2005-11-15 | 2011-09-06 | Entress Ab | uso de um ácido alfa-cetoglutárico ou de um sal farmaceuticamente aceitável de ácido alfa-cetoglutárico |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| EP2106791A1 (en) * | 2008-03-31 | 2009-10-07 | Biotempt B.V. | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation |
| KR101080271B1 (ko) * | 2009-03-31 | 2011-11-08 | 주식회사 웰스킨 | 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물 |
| WO2011126163A1 (ko) * | 2010-04-08 | 2011-10-13 | 주식회사 웰스킨 | 다이펩타이드를 포함하는 피부 미백용 조성물 |
| CN113018288A (zh) * | 2019-12-25 | 2021-06-25 | 同济大学 | α-酮戊二酸在制备药物中的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
| SE9303691D0 (sv) * | 1993-11-09 | 1993-11-09 | Gramineer Ab | New beverage |
| AU7984498A (en) * | 1997-06-25 | 1999-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Serum-free cell growth medium |
| US6846501B2 (en) * | 2000-04-12 | 2005-01-25 | Mid-America Commercialization Corporation | Traditional snacks having balanced nutritional profiles |
| DE10057290B4 (de) * | 2000-11-17 | 2004-01-08 | Fresenius Kabi Deutschland Gmbh | Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten |
| SE0201713D0 (sv) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| RU2211037C1 (ru) * | 2001-12-29 | 2003-08-27 | Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН | Препарат селективного действия и способ лечения остеоартрозов |
| AU2003294221A1 (en) * | 2002-09-13 | 2004-04-19 | Kenneth E. Miller | Method of alleviating pain via inhibition of neurotransmitter synthesis |
| AU2004237439B2 (en) * | 2003-05-07 | 2009-09-10 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
| US20050176807A1 (en) * | 2004-02-09 | 2005-08-11 | Friesen Kim G. | Composition and method for use in cartilage affecting conditions |
| JP2005312402A (ja) * | 2004-04-30 | 2005-11-10 | Kanazawa Univ Tlo Inc | グルタミン酸伝達系を利用した骨・軟骨疾患治療薬の評価方法 |
| PL368573A1 (en) * | 2004-06-17 | 2005-12-27 | Sgp & Sons Ab | Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals |
| PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| BRPI0618599A2 (pt) * | 2005-11-15 | 2011-09-06 | Entress Ab | uso de um ácido alfa-cetoglutárico ou de um sal farmaceuticamente aceitável de ácido alfa-cetoglutárico |
-
2006
- 2006-11-15 BR BRPI0618599-1A patent/BRPI0618599A2/pt not_active IP Right Cessation
- 2006-11-15 US US12/084,947 patent/US20090312427A1/en not_active Abandoned
- 2006-11-15 AU AU2006316059A patent/AU2006316059A1/en not_active Abandoned
- 2006-11-15 WO PCT/SE2006/050479 patent/WO2007058612A1/en active Application Filing
- 2006-11-15 RU RU2008123806/15A patent/RU2454999C2/ru not_active IP Right Cessation
- 2006-11-15 JP JP2008541124A patent/JP2009515953A/ja active Pending
- 2006-11-15 KR KR1020087014596A patent/KR20080074182A/ko not_active Application Discontinuation
- 2006-11-15 CN CN201010170906A patent/CN101843609A/zh active Pending
- 2006-11-15 CN CN2006800426722A patent/CN101309678B/zh not_active Expired - Fee Related
- 2006-11-15 EP EP06824548A patent/EP1951218A4/en not_active Withdrawn
- 2006-11-15 CA CA002629683A patent/CA2629683A1/en not_active Abandoned
-
2009
- 2009-05-19 HK HK09104552.3A patent/HK1126128A1/xx not_active IP Right Cessation
-
2010
- 2010-10-04 US US12/897,313 patent/US20110082086A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ607189A (en) | Materials and methods for improving gastrointestinal function | |
| JP2009515953A5 (ja) | ||
| JP2018012722A5 (ja) | ||
| HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
| WO2006062424A3 (en) | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system | |
| JP2013545745A5 (ja) | ||
| UA107112C2 (en) | Activator of soluble guanylate cyclase | |
| ES2855162T3 (es) | Régimen de administración de nitrocatecoles | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| JP2013520405A5 (ja) | ||
| JP2020517703A5 (ja) | ||
| JP2009534323A5 (ja) | ||
| NZ610911A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| JP2010506887A5 (ja) | ||
| US7846902B2 (en) | Dipeptide-comprising composition for oral administration | |
| JP2018523683A5 (ja) | ||
| RU2008123806A (ru) | Лекарственное средство, применяющееся при поражениях хряща | |
| JP2010536714A5 (ja) | ||
| JP2010532348A5 (ja) | ||
| JP2019501226A5 (ja) | ||
| NZ600931A (en) | Use of N-{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl} -3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-N-methyl-3-oxo-1-propanamine and perindopril for treating heart failure | |
| HK1109029A1 (en) | Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal | |
| UA102111C2 (uk) | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі |